Hydroxychloroquine in IgA nephropathy: a systematic review
Background Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. In the present systematic review, we aimed to summarize the evidence concerning the benefits and risks of HCQ therapy in IgAN. Methods Electronic data...
Enregistré dans:
Auteurs principaux: | Gabriel Stefan, Gabriel Mircescu |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Taylor & Francis Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a21e508e22924ad9b6fa8d86af66496c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
IgA Nephropathy Secondary to Ipilimumab Use
par: Sean C. Dougherty, et autres
Publié: (2021) -
IgA nephropathy with wilson's disease: A case report and literature review
par: Gaurav Bhandari, et autres
Publié: (2021) -
Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
par: Yebei Li, et autres
Publié: (2021) -
Identification of miRNA-mRNA network and immune-related gene signatures in IgA nephropathy by integrated bioinformatics analysis
par: Shi-Yao Wei, et autres
Publié: (2021) -
The prognostic role of heart rate recovery after exercise and metabolic syndrome in IgA nephropathy
par: Balázs Sági, et autres
Publié: (2021)